protein

Recombinant Human Alpha-Synuclein

MBS142948

0.02 mg

140 USD

Recombinant Protein

Recombinant Human Alpha-Synuclein

Alpha-Synuclein

SNCA Human; Alpha Synuclein Human Recombinant; Alpha-synuclein; Non-A beta component of AD amyloid; Non-A4 component of amyloid precursor; NACP; PD1; PARK1; PARK4; MGC110988; a-Synuclein; SNCA

alpha-synuclein isoform NACP140; Alpha-synuclein; alpha-synuclein; non A-beta component of AD amyloid; synuclein alpha-140; synuclein, alpha (non A4 component of amyloid precursor); Non-A beta component of AD amyloid; Non-A4 component of amyloid precursor; NACP

SNCA

SNCA; SNCA; PD1; NACP; PARK1; PARK4; NACP; PARK1; NACP

SYUA_HUMAN

E Coli

140

MDVFMKGLSK/ AKEGVVAAAE/ KTKQGVAEAA/ GKTKEGVLYV/ GSKTKEGVVH/GVATVAEKTK/ EQVTNVGGAV/VTGVTAVAQK/TVEGAGSIAA/ ATGFVKKDQL/ GKNEEGAPQE/ GILEDMPVDP/DNEAYEMPSE/EGYQDYEPEA.

Greater than 95.0% as determined by SDS-PAGE.

The protein (1mg/ml) contains 20mM Tris-HCl buffer (pH 7.5), 0.1M NaCl and 1mM MgCl2. Sterile filtered colorless solution.

Store at 4 degree C if entire vial will be used within 2-4 weeks. Store, frozen at -20 degree C for longer periods of time. For long term storage it is recommended to add a carrier protein (0.1% HSA or BSA). Avoid multiple freeze-thaw cycles.

RECOMBINANT & NATURAL PROTEINS; Recombinant Proteins; Synuclein

Description: a-Synuclein Human Recombinant produced in E Coli is a single, non-glycosylated polypeptide chain of 140 amino acids having a molecular mass of 14.4kDa(Real molecular weight on SDS-PAGE will be shift up). The Recombinant Human a-Synuclein is purified by proprietary chromatographic techniques. Introduction: a-Synuclein (amino acids 1-140), an acidic neuronal protein of 140 amino acids, is extremely heat-resistant and is natively unfolded with an extended structure primarily composed of random coils. a-synuclein has been suggested to be implicated in the pathogenesis of Parkinson's disease and related neurodegenerative disorders, and more recently, to be an important regulatory component of vesicular transport in neuronal cells. Moreover, recent studies have shown that a-synuclein has chaperone activity and that this activity is lost upon removing its C-terminal acidic tail (amino acids 96-140).

4507109

NP_000336.1

NM_000345.3

P37840

13,109 Da

Alpha-synuclein Signaling Pathway (137913); Alzheimer's Disease Pathway (83097); Alzheimer's Disease Pathway (509); Alzheimers Disease Pathway (672448); Amyloids Pathway (366238); Disease Pathway (530764); EGFR1 Signaling Pathway (198782); Parkin-Ubiquitin Proteasomal System Pathway (700638); Parkinson's Disease Pathway (83098); Parkinsons Disease Pathway (705377)

Alpha-synuclein is a member of the synuclein family, which also includes beta- and gamma-synuclein. Synucleins are abundantly expressed in the brain and alpha- and beta-synuclein inhibit phospholipase D2 selectively. SNCA may serve to integrate presynaptic signaling and membrane trafficking. Defects in SNCA have been implicated in the pathogenesis of Parkinson disease. SNCA peptides are a major component of amyloid plaques in the brains of patients with Alzheimer's disease. Four alternatively spliced transcripts encoding two different isoforms have been identified for this gene. [provided by RefSeq, Mar 2009]

SNCA: a member of the synuclein family. Abundantly expressed in the brain. Inhibits phospholipase D2 selectively. May integrate presynaptic signaling and membrane trafficking. Implicated in the pathogenesis of Parkinson s disease. A major component of amyloid plaques in the brains of patients with Alzheimer s disease. Two alternatively spliced isoforms transcripts have been identified. Protein type: Adaptor/scaffold. Chromosomal Location of Human Ortholog: 4q21. Cellular Component: Golgi apparatus; nuclear outer membrane; mitochondrion; rough endoplasmic reticulum; lysosome; fibril; extracellular region; terminal button; cell cortex; inclusion body; mitochondrial respiratory chain complex I; cytosol; actin cytoskeleton; platelet alpha granule membrane; synaptic vesicle; growth cone; axon; perinuclear region of cytoplasm; cytoplasm; plasma membrane; ribosome; cell junction; nucleus. Molecular Function: identical protein binding; protein domain specific binding; zinc ion binding; histone binding; kinesin binding; ferrous iron binding; microtubule binding; caspase inhibitor activity; magnesium ion binding; beta-tubulin binding; phosphoprotein binding; protein N-terminus binding; oxidoreductase activity; Hsp70 protein binding; calcium ion binding; dynein binding; protein binding; copper ion binding; phospholipase binding; phospholipid binding; tau protein binding; fatty acid binding; alpha-tubulin binding. Biological Process: regulation of long-term neuronal synaptic plasticity; negative regulation of serotonin uptake; regulation of acyl-CoA biosynthetic process; adult locomotory behavior; positive regulation of apoptosis; negative regulation of norepinephrine uptake; mitochondrial membrane organization and biogenesis; microglial cell activation; response to lipopolysaccharide; positive regulation of endocytosis; dopamine biosynthetic process; negative regulation of transcription from RNA polymerase II promoter; negative regulation of caspase activity; negative regulation of monooxygenase activity; fatty acid metabolic process; positive regulation of neurotransmitter secretion; regulation of dopamine secretion; negative regulation of dopamine uptake; negative regulation of histone acetylation; calcium ion homeostasis; negative regulation of exocytosis; response to magnesium ion; negative regulation of protein amino acid phosphorylation; behavioral response to cocaine; receptor internalization; phospholipid metabolic process; synapse organization and biogenesis; fibril organization and biogenesis; dopamine uptake; response to iron(II) ion; negative regulation of neuron apoptosis; positive regulation of receptor recycling; aging; caspase activation; response to drug; neutral lipid metabolic process; protein destabilization; regulation of macrophage activation; negative regulation of microtubule polymerization; regulation of glutamate secretion; positive regulation of peptidyl-serine phosphorylation; negative regulation of dopamine metabolic process; organelle ATP synthesis coupled electron transport; regulation of locomotion; synaptic vesicle endocytosis; positive regulation of release of sequestered calcium ion into cytosol; regulation of excitatory postsynaptic membrane potential; negative regulation of transporter activity; negative regulation of apoptosis. Disease: Parkinson Disease 4, Autosomal Dominant; Parkinson Disease 1, Autosomal Dominant; Dementia, Lewy Body

0.02 mg

140 USD

0.1 mg

205

1 mg

1030